Jacob Johnson
Stock Analyst at Stephens & Co.
(3.64)
# 783
Out of 4,876 analysts
77
Total ratings
47.46%
Success rate
8.32%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $237.76 | +0.94% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.58 | -8.75% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $8.24 | -27.14% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $30.09 | +99.40% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $199.08 | +58.23% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $410.29 | +65.74% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $123.25 | +37.93% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $5.06 | -1.19% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $2.21 | +397.74% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $24.70 | +53.85% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $7.25 | +134.48% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.40 | +78.57% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $51.33 | +69.49% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $218.13 | +78.79% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $7.10 | +153.52% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.36 | +154.24% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $21.25 | +36.47% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $113.69 | +14.35% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $150.25 | +150.92% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $237.76
Upside: +0.94%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.58
Upside: -8.75%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $8.24
Upside: -27.14%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $30.09
Upside: +99.40%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $199.08
Upside: +58.23%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $410.29
Upside: +65.74%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $123.25
Upside: +37.93%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $5.06
Upside: -1.19%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.21
Upside: +397.74%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $24.70
Upside: +53.85%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $7.25
Upside: +134.48%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.40
Upside: +78.57%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $51.33
Upside: +69.49%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $218.13
Upside: +78.79%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $7.10
Upside: +153.52%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.36
Upside: +154.24%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $21.25
Upside: +36.47%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $113.69
Upside: +14.35%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $150.25
Upside: +150.92%